Morgan Stanley started coverage on shares of Alumis (NASDAQ:ALMS – Free Report) in a research note published on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $36.00 price target on the stock.
Alumis Price Performance
ALMS stock opened at $12.50 on Tuesday. Alumis has a twelve month low of $10.45 and a twelve month high of $13.53.
Institutional Trading of Alumis
A hedge fund recently bought a new stake in Alumis stock. Towerview LLC acquired a new position in shares of Alumis Inc. (NASDAQ:ALMS – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 310,000 shares of the company’s stock, valued at approximately $4,123,000. Alumis comprises 2.7% of Towerview LLC’s investment portfolio, making the stock its 8th biggest position. Towerview LLC owned 0.66% of Alumis at the end of the most recent reporting period.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories
- Five stocks we like better than Alumis
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Investors Need to Know About Upcoming IPOs
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- With Risk Tolerance, One Size Does Not Fit All
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.